» Authors » Fabian Juliao-Banos

Fabian Juliao-Banos

Explore the profile of Fabian Juliao-Banos including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 127
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Parra-Izquierdo V, Otero-Regino W, Juliao-Banos F, Frias-Ordonez J, Ibanez-Pinilla E, Gil-Parada F, et al.
Crohns Colitis 360 . 2025 Jan; 7(1):otae081. PMID: 39834355
Background: The prevalence of colorectal cancer (CRC) in patients with ulcerative colitis (UC) is higher than in the general population, in Latin America there is a progressive increase of UC,...
2.
Parra-Izquierdo V, Gil-Parada F, Juliao-Banos F, Pavez-Ovalle C, Otero-Regino W, Frias-Ordonez J, et al.
Rev Gastroenterol Peru . 2024 Jul; 44(2):179-215. PMID: 39019814
Introduction: Endoscopy plays a fundamental role in inflammatory bowel disease (IBD), and becomes essential in diagnosis, treatment monitoring, and detection and management of complications. Materials And Methods: The Pan American...
3.
Parra-Izquierdo V, Frias-Ordonez J, Juliao-Banos F, Cuadros C, Romero Sanchez C, Florez-Sarmiento C
Gastroenterol Hepatol . 2023 Oct; 47(6):582-590. PMID: 37806342
Introduction: Tofacitinib is indicated in patients with moderate to severe ulcerative colitis (UC); however, given its rapid onset of action, it may constitute an alternative in patients with hospitalized severe...
4.
Parra-Izquierdo V, Frias-Ordonez J, Marquez J, Juliao-Banos F, Galindo P, Cuadros C, et al.
Gastroenterol Hepatol . 2022 Nov; 46(7):512-521. PMID: 36372256
Introduction: There are no studies on efficacy of tofacitinib for ulcerative colitis (UC) in Latin America. The aim of this study was to describe the efficacy and safety, in the...
5.
Gil F, Juliao-Banos F, Amador L, Castano N, Reyes J
Pharmacoecon Open . 2022 Aug; 6(6):837-846. PMID: 35943702
Objective: The aim of this study was to evaluate the cost effectiveness of tofacitinib versus other treatment options currently available in Colombia in naïve to biologics (first-line) and exposed to...
6.
Buie M, Quan J, Windsor J, Coward S, Hansen T, King J, et al.
Clin Gastroenterol Hepatol . 2022 Jul; 21(9):2211-2221. PMID: 35863682
Background & Aims: The evolving epidemiologic patterns of inflammatory bowel disease (IBD) throughout the world, in conjunction with advances in therapeutic treatments, may influence hospitalization rates of IBD. We performed...
7.
Juliao-Banos F, Osorio L, Carvajal J, Mosquera-Klinger G, Medellin A, Padron J, et al.
Gastroenterol Hepatol . 2022 Mar; 45(9):690-696. PMID: 35278506
Introduction: Perianal fistulizing Crohn's disease (CD) is a phenotype with a poor prognosis. There are no studies in our country. Our objective is to determine the clinical, sociodemographic and treatment...
8.
Yamamoto-Furusho J, Parra-Holguin N, Juliao-Banos F, Puentes F, Lopez R, Bosques-Padilla F, et al.
Medicine (Baltimore) . 2022 Jan; 101(3):e28624. PMID: 35060539
The aim of the present study was to describe the epidemiological and clinical characteristics of inflammatory bowel disease (IBD), including medical and surgical treatments, in several countries in Latin America...
9.
Juliao-Banos F, Kock J, Arrubla M, Calixto O, Camargo J, Cruz L, et al.
Medicine (Baltimore) . 2021 Feb; 100(7):e24729. PMID: 33607817
The incidence of inflammatory bowel disease (IBD) is on the rise in Latin America. The aims of this study were to examine epidemiologic trends of IBD in Colombia by demographics,...
10.
Juliao-Banos F, Galiano M, Camargo J, Mosquera-Klinger G, Carvajal J, Jaramillo C, et al.
Gastroenterol Hepatol . 2020 Nov; 44(5):346-354. PMID: 33199128
Introduction: The small bowel capsule endoscopy (SBCE) has revolutionised the study of small bowel diseases. The objective of this study is to determine the indications, findings and diagnostic yield of...